Title

Presentation

Insulet Corporation beats earnings expectations. Reported EPS is $1.44, expectations were $0.67. Insulet Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Fourth Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Deborah Gordon, Vice President, Investor Relations.

Deborah Gordon: Thank you. Good afternoon, and thank you for joining us for Insulet’s Fourth Quarter and Full Year 2023 Earnings Call. With me today are Jim Hollingshead President and Chief Executive Officer; and Lauren Budden, our Interim Chief Financial Officer and Treasurer. Both the replay of this call and the press release discussing our 2023 results, and 2024 guidance will be available on the Investor Relations section of our website. . Also on our website is our fourth quarter supplemental earnings presentation. We encourage you to reference that document for a summary of key metrics and business updates. Before we begin, we remind you that certain statements made by Insulet during the course of this call may be forward-looking and could materially differ from current expectations.

Please refer to the cautionary statements in our SEC filings for a detailed explanation of the inherent limitations of such statements. We’ll also discuss non-GAAP financial measures with respect to our performance, namely adjusted growth and operating margin, adjusted EBITDA and constant currency revenue, which is revenue growth, excluding the effect of foreign exchange. These measures align with what management uses as supplemental measures in assessing our operating performance, and we believe they are helpful to investors, analysts and other interested parties as measures of our operating performance from period to period. Additionally, unless otherwise stated, all financial commentary regarding dollar and percentage changes will be on a year-over-year reported basis with the exception of revenue growth rate, which will be on a year-over-year constant currency basis.

With that, I’ll turn the call over to Jim.

Jim Hollingshead: Thanks, Deb. Good afternoon, and thank you for joining us. With our strong Q4 2023 results, we kept off another transformational year, in which we firmly established Insulet as the market leader in automated insulin delivery. In 2023, we realized a 30% revenue growth, which marked our eighth consecutive year of 20-plus percent revenue growth and represented dollar growth of almost $400 million. We accomplished this while also significantly expanding margins and generating positive free cash flow. Our record new customer starts in 2023, fueled our global growth and our Omnipod 5 AID system, which generated $1 billion in revenue in 2023 is transforming diabetes management. We entered 2024 with significant momentum, and we are looking forward to a year of many growth catalysts ahead.

On today’s call, I want to do three things: first, discuss our financial results and market traction. Next, I’ll provide an update on the continuing progress of our clinical efforts and then review key developments in our innovation pipeline. Our fourth quarter revenue once again exceeded our expectations with total Omnipod growth of 35%, including U.S. growth of 43%. Part of our outperformance was driven by U.S. distributors placing additional orders near the end of the quarter, which we had not factored into our guidance. We’ll provide more detail on this in a few minutes. Yet even without these additional orders, we closed out 2023 ahead of our expectations, including healthy margin expansion. These are remarkable results, and I want to thank our global team for their execution and dedication.

We are proud of the incredible impact the Omnipod product platform is having on people with diabetes. We recently achieved milestones of roughly 425,000 active global customers on the Omnipod platform, which represents growth of approximately 25% from this time last year. This also includes almost 250,000 customers on Omnipod 5, which has proven to be revolutionary. And Omnipod DASH continues to drive strong new customer starts in our U.S. type 2 diabetes market as well as in most of our international markets. We are thrilled that our unique technology is making a meaningful impact on the diabetes community, advancing our mission to improve the lives of people with diabetes around the world. Omnipod 5 is the only FDA cleared, fully disposable pod-based AID system.

This makes our product unique and clearly differentiated from competitors’ offers. These product attributes underpin our competitive advantages and are key to fueling our growth, further establishing our leadership position and expertise in the diabetes market. The fully on-body wearable AID experience of Omnipod 5 dramatically reduces the daily burden of living with diabetes. And its simplicity, ease of use and broad and affordable access are also key drivers of its rapid adoption. For almost a decade, we have significantly invested in U.S. pharmacy channel access, including building the infrastructure, developing key pharmacy relationships, creating an easy onboarding pathway and building deep in-house expertise, all of which has resulted in a strong and leading channel access we have today.

We continue to strengthen Omnipod’s access and affordability, including our innovation pipeline that will go through this channel by building on our advantages. In the U.S., Omnipod 5 continue to represent the vast majority of our new customer starts in Q4, and we expect this trend to continue. In addition, customer retention remains strong. The mix of U.S. new customer starts coming from multiple daily injections and legacy tubed pumps continued at an estimated 80-20 percentage split. Today, even with improved technology, most people using insulin still use MDI as their mode of care. More than 60% of people with type 1 diabetes in the U.S. are on MDI and the vast majority of people with type 2 diabetes are using daily injections. Therefore, bringing people out of MDI and on to Omnipod remains the largest opportunity for us, and we continue to drive pump penetration and share gain in both the type 1 and type 2 markets, strengthening our leadership position.

Omnipod 5 not only drove our number one position for U.S. and customer starts in 2023, it was the most prescribed AID system in the U.S. This is because a growing number of health care providers are writing scripts for it. In Q4, we saw another increase in prescribers growing to over 18,500, up from 17,000 in Q3. We speak with many HCPs and it is clear that Omnipod 5 is the winning choice for AIB. It is extremely gratifying to see the growing demand, confidence and adoption which have led to a growing number of scripts HCPs now write for our system. Our strong new customer starts included continuing adoption of Omnipod in the U.S., type 2 diabetes market. We estimate that no more than 5% of people with type 2 diabetes who need intensive insulin therapy are currently using any kind of pump.

And we know that we are already the market leader in that space. We are confident that Omnipod will prove to be a simple and compelling solution for the millions of people globally with type 2 diabetes who today need insulin therapy as a part of their diabetes care regimen as well as the future millions who will naturally progress to requiring insulin as a part of their care. We are well positioned to bring all of the benefits of the Omnipod platform with people with type 2 diabetes both today and in the future. In the fourth quarter, type 2 diabetes patients represented between 20% and 25% of our U.S. new customer starts across our Omnipod suite of products. While Omnipod DASH, with its type 2 indication for use is the leading insulin pump operating in this market, we look forward to marketing Omnipod 5 to type 2 patients once we have an expanded indication.

The underlying demand is apparent. We expect the last participant to complete our type 2 pivotal trial in the coming weeks, and we plan to submit results to the FDA by the end of 2024 for an expanded indication. We are confident this will be another catalyst that will fuel our growth trajectory, allow us to serve more patients and help us deliver on our mission. We look forward to sharing study results at ADA this June. The success of Omnipod 5, including its early yet powerful impact in 2 of our European markets, led to another strong quarter of new customer starts globally. Internationally, we realized a notable sequential increase in new customer starts, driven by the impact of Omnipod 5 that’s having in the U.K. and Germany. Our early success in these countries supports our confidence that it will continue to transform diabetes care and position us as a market leader everywhere Omnipod 5 is available.

We remain on track with our Omnipod 5 plus G6 European launch plans with the aim of making Omnipod 5 accessible to the majority of our European customers by the end of 2024. We are also thrilled to begin our journey launching Omnipod 5 integrated with Abbott’s Freestyle Libre 2 Plus sensor. I’ll speak to this new opportunity in a moment. In addition to our type 2 pivotal study progress, we are meaningfully advancing several other clinical initiatives. We are excited to attend the ATTD International Conference in Italy in a couple of weeks where we will present data for the Omnipod 5 plus G6 randomized controlled trial. This RCT compared Omnipod 5 to non-AID pump and included study sites in the U.S. and France. We are thrilled to have recently published in the Diabetes Technology and Therapeutics Journal real-world evidence from almost 70,000 people with type 1 diabetes, demonstrating Omnipod 5’s effectiveness in a large, diverse population.

The data are impressive and demonstrate the strength of the Omnipod 5 algorithm in the real world delivering leading time in range and very low hypoglycemia, reinforcing Omnipod 5 as the obvious choice for clinical outcomes and personalized diabetes care. Central to everything we do is our mission to simplify life for people with diabetes. We want to make it easier for people to get prescribed therapy, get set up on therapy and use therapy consistently over time. This is the point of our evolution feasibility study taking place in New Zealand. Our intent is to have a next-generation algorithm that will further drive simplicity of use. We completed the first feasibility study in participants with either type 1 or type 2 diabetes, commencing initially in supervised hotel setting and then progressing to at-home use.

We are pleased with the preliminary results and are analyzing the data and making modifications for the next round of subjects. We will present early feasibility results at ATTD. Lastly, we continue to actively enroll participants in our RADIANT study in France, the U.K. and Belgium, which is our Libre 2 integration trial. We began enrollment in September 2023, which is now halfway complete. Feedback has been tremendous and physicians new to Omnipod 5 appreciate its simplicity and potential to reach many more pump-naive users. As a reminder, both our G6 and Libre 2 studies are designed to provide the evidence we need to elevate Omnipod 5 status as superior first-line therapy and help drive our pricing and market access initiatives as we further roll out Omnipod 5 with multiple sensors across our international markets.

I’ll now provide an update on our innovation progress and we’ll focus on three key areas: expanding the Omnipod 5 platform, moving upstream in the type 2 market with Omnipod Go and building our digital and data capabilities. Many of you have heard us say that our current Omnipod 5 system is our “minimum” viable product. That’s easy to forget given how quickly the market has adopted Omnipod 5 and made it the leading offer. Our current version is on only one operating system, Android. It is integrated with only one continuous glucose monitoring partner, Dexcom and until recently, was commercialized with only G6, and it contains our first-generation algorithm. This is about to change with platform extensions that will strengthen our leadership, deepen our competitive moats and allow us to open up Omnipod 5 to many more customers.

To start, we are excited to have commenced our U.S. limited market release of Omnipod 5 with G7 over the last 2 weeks. This initial release will allow us time to test the market and build product at scale to prepare for what we are confident will be a very successful full market release of G7 this year. We anticipate an acceleration in new customer starts following a full launch, which will help to fuel our revenue growth more meaningfully in 2025 and beyond. We are also on track with our planned limited market release of Omnipod 5 with Libre 2 Plus in the first half of this year in the Netherlands and U.K. made possible by the CE Mark approval we received earlier this month. We are excited that the option for customers to use Omnipod 5 with both G6 and Libre 2 Plus will enable us to reach many more patients.

Our recent and upcoming CGM integrations are important milestones in providing choice to tens of thousands of customers who want to use Omnipod 5 and we believe both integrations will be a significant catalyst for our growth in 2024 and beyond. Rounding out near-term innovation, we are planning for our U.S. launch of Omnipod 5 with the G6 system with our iOS app this year. This will mark a major innovation milestone because so many of our U.S. customers use Apple iPhone and prefer to carry only one phone. Another innovation that will allow us to reach more people and further expand our total addressable market is Omnipod GO, a solution designed for individuals with type 2 who naturally progress to requiring basal-only insulin and want a simple way to receive their daily dose, while avoiding the burden of injections.

Our commercial pilot is underway, and it will help us refine our commercialization plans. Omnipod DASH has already made Insulet the leader in insulin delivery for people with type 2 diabetes. And with Omnipon GO, we are well positioned to move upstream in the patient care pathway. When we achieve clearance for Omnipod 5 in the type 2 market, we will bring all of the advantages of our AID system to this market. With these 3 products, our aim is to deliver an Omnipod portfolio that meets the full range of needs of people with type 2 who require insulin as a part of their care. We are excited about our innovation in the space and our ability to address the unmet needs that exist in this patient population. It is a massive global market that we expect will continue to grow, and we have the clear lead to pursue this market opportunity.

We are also excited to build on our digital and data capabilities. One of the breakthrough features of Omnipod 5 is the real-time data provided by SIM cards in every controller. We constantly hear from physicians and patients how much they appreciate not needing to plug in for real-time usage data and 100% cloud connectivity has already given us the opportunity to publish the largest, real-world data set on AID. Over time, we plan to use the data to speed our product development, further improve the user experience, streamline physician workflows and build on our competitive advantages. We also continue building digital and data-driven products to simplify diabetes management for both customers and caregivers. In closing, Insulet continues to set the standard for the industry.

With a strong 2023 behind us, we see multiple catalysts in the coming year and beyond. We are confident we will drive significant growth and continued success. I want to thank our Insulet global team for your dedication and deep passion for our customers and your commitment to delivering innovation. You are the reason for our success and our ability to continue to drive our mission to simplify life for the millions of people with diabetes around the world. With that, I will turn the call over to Lauren.

Lauren Budden: Thanks, Jim. 2023 was another exciting year for Insulet, and the fourth quarter was no exception. We have strong momentum with many catalysts that will drive revenue growth and margin expansion in 2024 and over the long term. In Q4, we generated strong global, new customer starts fueled by the continued high demand for Omnipod 5, not only in the U.S. but also in our first 2 European markets. . As a result of our growing customer base, we delivered 37% revenue growth in Q4, driven by global Omnipod growth of over 35%. We benefited from a shift in order timing and an increase in days on hand at certain pharmacy distributors, which I’ll speak to in a moment. Without these benefits, our results still exceeded these guidance ranges.

On a reported basis, for total revenue, foreign currency was a 130 basis point tailwind compared to Q4 of last year. U.S. Omnipod revenue growth was 43%, which continues to be driven by our annuity-based model and growing U.S. pharmacy volume. This includes an increasing volume contribution from Omnipod 5 and the related premium for pods in the U.S. pharmacy. Pharmacy channel access continues to be a benefit for the many reasons Jim spoke to, and our efforts to drive increased volume through this channel have resulted in almost all of our U.S. volume going through the pharmacy channel. The recurring net volume benefit we recognized in Q4 from new customers who received their starter kits and first refill orders was in line with our expectations and remain consistent with Q3 levels.

We expect this trend to continue. Also as expected, the same net volume benefit from existing customers converting to Omnipod 5 was immaterial since the vast majority had already previously converted. In Q4, U.S. revenue benefited from 2 dynamics not previously contemplated in our guidance. First, our largest U.S. pharmacy wholesalers collectively placed an estimated $20 million to $25 million in orders that were accelerated from the first quarter of 2024 in advance of our implementation of a new ERP system at the start of 2024. The second benefit was an increase in estimated channel inventory days on hand of approximately $10 million to $15 million as pharmacy distributors returned to their normal levels. As a reminder, in the first half of 2023, we called out a reduction in inventory days on hand below normal levels.

What this boils down to is approximately $30 million to $40 million in revenue in Q4 that we had not anticipated, contributing approximately 12 points to our U.S. revenue growth. We are proud of our fourth quarter U.S. performance, especially given the tougher comparison due to the Omnipod 5 full market release in August of 2022. Additionally, new customer starts in Q4 were slightly down from Q3 as expected as the market is moving from Dexcom’s G6 sensor to G7. We are excited to have launched our U.S. limited market release of Omnipod 5 with G7. And as Jim shared, we expect new customer starts to accelerate throughout 2024 as we ramp our commercial efforts. Overall, our U.S. business and related revenue growth are very strong, fueled by Omnipod 5’s success and continued robust demand.

International Omnipod revenue increased 12.5%, which was above our expectations. Growth was primarily driven by continued strong adoption of Omnipod DASH and to a smaller degree, a benefit from our Omnipod 5 launches in the U.K. and Germany, both of which drove notable increases in new customer starts. On a reported basis, foreign currency was a 550 basis point tailwind over the prior year, which was approximately 250 points favorable versus our guide. In Q4, our estimated global attrition and utilization trends remained stable. Drug Delivery revenue was almost $9 million, representing a $5.5 million increase, which was above our guidance range due to timing. Gross margin was 70.9%, up over 1,200 basis points. Excluding the impact of the 2022 medical device corrections, adjusted gross margin increased 620 basis points to 70.7% in Q4 2023.

This exceeded our expectations due to favorable manufacturing costs and product mix. The increase in adjusted gross margin was primarily driven by improved manufacturing efficiencies and favorable mix that included a premium from volume growth in the pharmacy channel. Partially offsetting the favorable contributors were expected higher production costs as U.S. manufacturing continues to ramp and become a larger portion of our total production. Operating expenses increased in line with our expectations as we invested in our business to support our strong growth trajectory, including gearing up for near-term product launches globally. Adjusted operating margin was 20.7% and adjusted EBITDA was 26.9% of revenue. Both were above our expectations, primarily due to the $30 million to $40 million revenue benefit I mentioned, which had an estimated 360 basis point favorable impact on adjusted operating margin.

To a lesser extent, both outperformed due to our higher-than-expected gross margin. Turning to cash and liquidity. We ended the year with over $700 million in cash and the full $300 million available under our credit facility. At the end of January, we successfully repriced our Term Loan B at a lower interest rate, which will reduce interest expense on an annualized basis by almost $2 million. We also achieved the milestone during the year of turning free cash flow positive, generating approximately $70 million in 2023. We continue to strengthen our financial position, giving us the flexibility to invest throughout our organization to drive long-term sustainable growth while at the same time expanding our margins and generating positive free cash flow.

Now turning to our 2024 outlook. We continue to expect another year of large dollar growth even with the significant volume benefits realized in 2023, most notably from our Omnipod 5 ramp. We expect to approach total company revenue of $2 billion at the high end of our guidance range. For the full year, we expect total Omnipod revenue growth of 13% to 18% and total company revenue growth of 12% to 17%. As a reminder, our total company growth expectations exclude approximately 3 points due to the estimated $20 million to $25 million in orders that were accelerated to the fourth quarter of 2023. For U.S. Omnipod, we expect revenue growth of 16% to 21% driven by strong Omnipod 5 adoption as well as recurring revenue from Omnipod DASH and the benefits of our annuity model and pharmacy channel access.

As a reminder, we have a tougher comparison in 2024, resulting from the significant 2 scripts and retail channel net stocking volume benefits in 2023. In addition, our expectations exclude approximately 4 points of growth due to the estimated orders that shifted into 2023. When factoring this into both periods, our normalized expectation for 2024 at the high end of our range is in line with the color we provided on our third quarter call of mid-20% growth. We anticipate new customer starts in the first half of 2024 to be slightly lower than the levels we had in the second half of 2023 due to normal seasonality trends, and we expect an acceleration in the second half of 2024 following a full market release of Omnipod 5 with G7. Also, as a reminder, estimated revenue from Omnipod 5 with our iOS app and from Omnipod GO is expected to be immaterial.

We also currently expect the cadence of our revenue growth to be weighted more towards the second half of 2024 due to the timing of new customer starts, partially offset by the Q4 2023 stocking benefit. For international Omnipod, we expect revenue growth of 7% to 10%, which is in line with the 2024 color we previously provided of high single digits. On a reported basis, we are assuming no foreign currency impact. We expect growth to be driven by ongoing Omnipod DASH adoption and from our recent Omnipod 5 launches in the U.K. and Germany. We expect continued headwinds in the countries where we do not yet have Omnipod 5 to partially offset this growth. We are excited to enter our first European markets in the first half of 2024, with Omnipod 5 integrated with Abbott’s FreeStyle Libre 2 Plus and to launch Omnipod 5 with G6 in another market around the same time.

As a reminder, given the nature of our annuity model, we expect these launches to more meaningfully contribute to our growth rate in 2025. We continue to expect the first half of the year to be in the high single digits range and to accelerate in the second half of the year to a range of high single digits to low double digits, primarily due to a more meaningful contribution from our Omnipod 5 U.K. and Germany launches and, to a lesser extent, the additional launches in 2024. Lastly, for Drug Delivery, we expect a 50% to 60% decline in line with the 2024 color we previously provided. Turning to 2024 gross margin. We expect a range of 68% to 69% and anticipated benefit from favorable product mix and manufacturing efficiencies. Partially offsetting these tailwinds are higher costs associated with our new product launches.

We expect gross margin in the second half of the year to be higher than the first half due to accelerating revenue throughout the year and continued manufacturing efficiencies. In 2024, we plan to expand both gross and operating margins while driving market growth. We expect operating expenses to increase as we invest in R&D and clinical and expand our sales force and other functions to support our commercial efforts and growth initiatives, including our near-term product lines. Our sales force expansion includes hiring some reps specifically focused on pediatrics, a population for which Omnipod has always captured a large share. Even with increased investments, we have many opportunities to significantly expand margins and increase shareholder value, and we remain committed to doing just that.

We expect operating margin to be approximately 13%, up approximately 100 basis points from 2023 adjusted operating margin. When factoring in the 130 basis point year-over-year unfavorable impact in 2024 from the $20 million to $25 million shift in order timing, we expect operating margins to be approximately 200 basis points higher in 2024 over 2023. We expect operating margin to significantly improve in the second half of the year over the first half due to revenue ramping during the year and continued manufacturing improvements. We have many catalysts for growth in 2024 and considerable opportunities to drive further margin expansion over the near and long term coming from scaling the business efficiently even with the continued focused investments in our robust innovation pipeline and commercial efforts.

We expect capital expenditures to almost double from 2023 due to the timing of spend to support our planned 2024 production at our new Malaysia manufacturing facility as well as investments to support continuous improvement efforts in our other manufacturing locations and to a lesser degree, investment in IT infrastructure. Turning to our first quarter 2024 guidance. We expect total Omnipod growth of 15% to 18% and total company growth of 17% to 20%. Our total company revenue expectations exclude approximately 6 points of growth due to the orders that shifted into 2023. For U.S. Omnipod, we expect growth of 19% to 22%, which excludes over 8 points of growth due to the orders that shifted into 2023. For international Omnipod, we expect growth of 5% to 8%.

On a reported basis, we estimate a favorable foreign exchange impact of approximately 100 basis points. Finally, we expect Q1 drug delivery revenue to be approximately $5 million to $6 million. In conclusion, we delivered another quarter and year of significant financial performance and strategic execution. We have strong momentum at the start of 2024 with many catalysts ahead and as a result, we are in a fantastic position to continue to grow and efficiently scale our business. The global market opportunities for Insulet are tremendous, and we will continue to invest in innovation with an increased commitment to significant margin expansion. We are well positioned to drive long-term value creation for our shareholders and to deliver on our mission for our customers.

With that, operator, please open the call for questions.

See also 16 Best Exercises For Lower Back Pain and 15 Hot Penny Stocks On the Move.

Operator: [Operator Instructions] Our first question comes from the line of Travis Steed with Bank of America.

Travis Steed: I wanted to ask about the guidance on U.S. growth. If you just do the math using year-over-year growth rates, you get 2% from stocking which implies like 18% to 23% versus kind of the mid-20s guide before. But I know you said in the script like there was really no change to guidance. And I guess if you just do it on dollars, you kind of get to the same place. Maybe you can just provide some clarification on the U.S. guide and how it’s changed versus 3 months ago.

Lauren Budden: So yes, just in November when we gave guidance, it really hasn’t changed much in our view. As I mentioned in the prepared remarks, we had a $30 million to $40 million shift in revenue — or sorry, incremental revenue. Of that $10 million to $15 million was an increase in days on hand inventory levels. And so that, we have seen the inventory levels brought down earlier in the first half of the year. So that was a piece of that. The rest of it, the $20 million to $25 million was the shift that we saw in order timing from Q1 to Q4. So for that, that was in advance of our ERP. And if you were to normalize for that, which contributed about 12 points benefit to our U.S. revenue growth rate, we really achieved the high end of our guidance range there.

Operator: Your next question comes from the line of Robbie Marcus with JPMorgan.

Rohin Patel: This is actually Rohin on for Robbie. You came off a really great year on both the top and bottom lines with continued health and new patient growth in the U.S. as well. I was wondering, if you could elaborate more on some of the key growth drivers to new patient growth as well as margin expansion in 2024 and beyond.

Jim Hollingshead: Thanks, Rohin. I’ll take the first shot at that, but then I’m sure Lauren may want to comment as well. I mean I think that the main — there’s just a core driver to new customer starts for us, which is Omnipod 5 is clearly the most preferred product in the market. We lead in new customer starts. Wherever we take Omnipod 5, we lead in new customer starts for people coming up with MDI, and we continue to take a lot of competitor share. So the Omnipod 5 offering as it exists today is already an underlying growth driver for us. Then there are a number of things that we’ll bring to market in 2024 that will drive a lot of growth. We’ll be able to drive international expansion for Omnipod 5 in 2024 as we said. We’re aiming to get into the G6 product to market into the Netherlands along with sensor of choice in U.K., Netherlands in the first half.

And as we’ve said, by the end of 2024, we expect to have Omnipod 5 available to the majority of our customers in our European markets. And then obviously, G7. So we’re really excited to have been able to accelerate our G7 LMR by a couple of weeks, a little bit earlier than our expectation. We’ve been in market now with the LMR for not quite 3 weeks, about 2.5 weeks and aim to bring a full market release of G7 during the year, which we think will continue to drive new customer starts for us. So we’re very, very excited about that. So there’s a lot of catalysts coming in our innovation pipeline that will drive growth on top of the already existing leading market position for Omnipod 5. But I’m sure, Lauren, will want to pick up on — at least I’m guessing, Lauren, you want to pick up on some of which you asked her as well.

Lauren Budden: So yes, we have a lot of additional opportunities for improvement, especially if we exceed our revenue targets and you saw that in Q4, we had tremendous operating margin. It was over 20% on an adjusted basis. And if you normalize for the revenue shift, it was about 17%. So if we can exceed revenue, we can have a lot of incremental margin opportunity. But keep in mind that we will be balancing that with investment. So as Jim mentioned, we have a lot of new product launches coming up, and we want to make sure we’re executing on our strategic imperatives to drive future growth in 2025 and beyond. So we will be balancing that with the revenue drop through to the bottom line.

Operator: Your next question comes from the line of Jeff Johnson with Baird.

Jeff Johnson: Jim, you’re encouraging to hear that O5 in the majority of the EU markets by the end of 2024. That’s the good thing. I didn’t hear anything on G7 integration with O5 in Europe. In 2024. I know you are specifically not providing that, but any color you can provide there, especially in the context of talking about your U.S. growth accelerating in 2024, just as the market is starting to move to G7 and you need to get that FMR on G7 out there in the U.S. to then take advantage of that move to G7 that Dexcom has seen. So I guess, it sounds like that lack of G7 integration could be a headwind in ’24 offset by the O5 expanding in EU. So just how do we think about those 2 disparate factors, if you will?

Jim Hollingshead: Yes. Thanks, Jeff, and nice to hear from you. So one way to think about this is that we’re prioritizing the sequencing, right? And so we know that driving the integration with sensors and driving sensor of choice as we call it for customers is really, really important. And you can see — in a way, you can see what we’re doing here because we’re already into LMR with G7 in the U.S. We’re going to learn a lot about that integration here. We feel very comfortable with it as it has been through [indiscernible]. But you put the LMR out in the market to see the product in the wild, right, and make sure you’re happy with it, make sure customers are having a great experience. And we’ll learn from that LMR in a way that will allow us to accelerate G7 in the U.S. and then internationally.

We haven’t guided the timing on anything outside of the US on G7 but the LMR is important in that way. Very similarly, we’re looking to be able to accelerate our LMR for the Libre 2 Plus integration in Europe and working hard to get that to market. The experience we’re having right now with the RADIANT trial, which is our Libre integration trial in Europe suggest that that’s a great wear experience for customers as well. And so you can see we’re accelerating that LMR in Europe. We’ll learn from that LMR too. So — and we haven’t given any timing guidance on Libre for the U.S., but you can see what we’re doing is we’re kind of parallel processing the 2 LMRs to maximize our learning and kind of optimize our resource use across the geographies, if that makes sense.

Very high priority for us to get sensor integrations up and running to give choice and also because what we want to do is we’re really prioritizing making sure that customers that want to be on Omnipod 5 can get on Omnipod 5. And that’s our top priorities to drive this. It’s really — it’s proven on — Omnipod 5 has proven to be a revolutionary offer. Lots of people want to be on Omnipod 5. So we’re working hard to make sure we get the sensors integrated as quickly as we can into the various geographies as quickly as we can to provide that kind of access and option to customers and working hard to optimize the way we’re doing it, so we can maximize our learning in time to market.

Operator: Our next question comes from the line of Jayson Bedford with Raymond James.

Jayson Bedford: Just on international, is your expectation that you’ll be able to capture price with OP5? And then kind of what is the gating factor here in not launching into — and launching into new European geographies a little quicker than fully by year-end.

Jim Hollingshead: Yes, Jason, great question. It has been — we’ve talked about this consistently in the past. So what we want to do with Omnipod 5 is generate the evidence we need, which is we’re doing with our G6 RCT, which I mentioned in the comments we’re doing with our RADIANT trial. We’re generating the evidence we need to establish Omnipod 5 as a first-line offering and then go and negotiate for reimbursement across our international markets. Reimbursement levels that are commensurate with the extra value we’re creating with the Omnipod 5 offering. And so our goal is to drive a price premium. It’s a little bit different from what we did in the U.S. because when we launched Omnipod 5 in the U.S., we launched it into the pharmacy channel, pricing parity with DASH because we knew that would streamline time to full coverage in the market.

So we got to full coverage. In the European markets, what we need to do is make sure we’re negotiating kind of reimbursement body. It’s different in every market, and there’s tenders, there’s ministries of health and so on, but we need to negotiate those market by market, but we have to generate the evidence that’s required to be able to have that conversation. So far, we’ve been very successful with that. So working in the U.K., we’re very comfortable with where we’ve landed with reimbursement levels in the U.K., working in Germany and so on. And so we’re going to continue to drive that and work really hard to achieve a premium for Omnipod 5 everywhere we launch it. And then remind me the second part of your question, it was all the gating factors.

Gating factors, it’s a little bit different by every market. Sometimes it’s reimbursement — sometimes it’s sort of cloud connectivity. We’ve made a lot of progress on that latter technical front. And then it’s just preparing for commercial launch and making sure that everything is lined up to do that. We’re making terrific progress. And as we’ve said, I just want to clarify, actually, I think Jeff just said that we said we’d be in the majority of our markets. We haven’t said that. What we’ve said is that by the end of 2024, there may be a technical problem on the call. What we said by the end of 2024, we will have the majority of our European customers have Omnipod 5 available.

Operator: Our next question comes from the line of Larry Biegelsen with Wells Fargo.

Larry Biegelsen: I wanted to follow-up on Travis’ question on the guide. So I guess the crux, Lauren, of my question is, did anything change from the Q3 call and from JPMorgan. So you said the high end — when you make these adjustments, you said the high end of this guidance implies mid-20s. So why the high end? I mean is there — was there an incremental change? And I think you said at JPMorgan that new starts would grow year-over-year in 2024. I didn’t hear that in your comments today. And I’m just curious, Lauren, your guidance philosophy in general, has anything changed from historically Insulet is guided pretty conservatively.

Jim Hollingshead: Larry, we’re having a technical problem on the call. And so I’m going to take my best shot at answering your question. And so on guidance, nothing has really changed from our guidance. I think that the guide we’ve given on revenue and on new customer starts, I mean, it’s pretty consistent with the color we gave on the November call. And the big move is actually the unusual order pattern where we had $20 million to $25 million of revenue pulled forward. We’re still guiding to ramping new customer starts in 2024. The change — the only real change in the guidance that we’re giving compared to color is that we’re guiding to a 13% — roughly a 13% operating margin for 2024, which is actually an increase from the color we gave on the November call.

And there are a number of opportunities for us to do that. But we delivered really strong operating income through 2023 and actually exceeded what we had guided to for 2023 because if you remember our guide in 2023, it was high-single-digits, which you call it like 9.5% plus, and we ended up delivering well above that. And we’re now guiding to 13%, which as Lauren explained in the prepared comments, represents 100 basis points over what we achieved at the end of 2023, but more than 200 basis points or roughly 200 basis points above what we would have achieved without the revenue pull forward. That 13% OI guide, is the only real change from the color we gave in November, if that makes sense.

Operator: Our next question will come from the line of Margaret Kaczor with William Blair.

Margaret Kaczor: Wanted to maybe follow up on HCP prescribers. Obviously, that’s a number that continues to grow quarter on quarter on quarter. Curious if you can provide any details around that? Are these folks routinely prescribing? Are you seeing growth in number of prescriptions? Maybe how does this compare to the number of pump prescribers in the U.S. And sorry, it’s a long-winded question, but it really gets at this concept of how can you open up the part of the intensive insulin patient population, type 1 or type 2 that is being seen outside of the Endo’s office and really scale that effort.

Jim Hollingshead: Thanks, Margaret. It’s a great question. And again, I’ll start and if Lauren wants to chime in on the back, I’d welcome that. Just to go back to context, we actually didn’t put this in the prepared comments this quarter, but we’ve — in the past, we’ve pointed out the endo market is somewhere around 70 — 7,000 to 7,500 endos in the U.S. We know that a number of prescribers that we have are either endocrinologists themselves or their so-called physician extenders, which will include nurse practitioners and physician assistance, but we’re clearly getting prescriptions beyond that. We’re clearly getting prescription writing outside of endo practices, in PCP practices and in smaller practices, and that dynamic continues to grow, and we can see it in our own data.

We don’t have perfect insight into it out of the various available data. But we can see we’re reaching more and more health care practitioners. And that’s we believe we’re doing that through word of mouth, through our promotion activities, which include both direct-to-patient activities and also direct-to-physician promotional activities online. And then the other thing I’ll say is that it’s been very, very powerful for us, sort of along the same lines. The Omnipod GO commercial pilot has proven to be a terrific investment for us this year because what we’re learning — we’re learning a lot more about what happens in the primary care channel for people living with diabetes. And just a couple of things we’re seeing, we’ve learned a lot about the target patient population for Omnipod, we’ve learned that primary care practices when they think pump, they think the [indiscernible] thing with a tube that they would never prescribe and then when they see Omnipod, there’s a little bit of a head dynamic, and they say, “Wait, you know what, that’s so easy.

My patients could do that. We could do that.” And so we’re very confident we’re going to be able to drive demand for the Omnipod platform across primary care. And I think we’re seeing more type 1 patients than we anticipated in the primary care channel. So to your point, we’re very optimistic that as we continue to drive learnings out of our Omnipod Go pilot, we’re going to be able to find a new kind of new avenues for driving demand for Omnipod and really driving pod therapy — Omnipod therapy into the world where patients need it most. And so we’re very optimistic about that. And so we continue to see that trend as a positive signal for us, but we’re really excited about what we’re learning out in the world with our commercial pilot as we go.

Operator: Your next question will come from the line of Josh Jennings with TD Cowen.

Josh Jennings: I was just hoping to better understand pricing dynamics through the pharmacy channel in the U.S. for Omnipod 5 and DASH. Was reimbursement stable that Insulet was receiving for Omnipod 5 and Omnipod DASH in ‘23? And how should we factor in reimbursement levels and pricing for Omnipod 5 and DASH in 2024?

Lauren Budden: Yes. So really, it’s more about a volume business at this point. We did get a big price lift throughout 2023 from the conversions into the pharmacy channel. But as we’ve mentioned previously, those conversions are largely complete by this point. So we’re not seeing that going forward. We did have a price increase like we normally do in early September, which was pretty minimal. It’s just under 3% kind of in line with the cost of living adjustment. So just keep in mind there, though, we don’t see the full benefit of that because some of it goes to the DDM in terms of rebates and to the wholesaler fees. So at this point, for 2024, I would pretty much say that you should focus on the volume, not the price has leveled off. The great news is that we are getting that continued price lift going forward, but it shouldn’t be an incremental change.

Operator: Your next question comes from the line of Joanne Wuensch with Citi.

Unidentified Analyst : This is Anthony on for Joanne. 2024 is kind of investment year, maybe 2025 as well. But can you talk over the longer term, 2026 and beyond where gross margins and operating margins potentially could go and how you get there?

Lauren Budden: Yes, I’m happy to start off and then Jim feel free to add on. Yes, we definitely feel like we have room for expansion, both on margin and gross margin in the near term and in the longer term. We did great in Q4, and we have lots of opportunities as we’re setting up with the product launches that we have this year that will accelerate the top line and be able to allow us to drop more through. We haven’t put out guidance beyond 2024, but we are planning on doing a long-range plan later in this year.

Operator: Your next question will come from the line of Matthew O’Brien with Piper Sandler.

Matthew O’Brien: It is going to be one question, I promise. The first part is just more clarification kind of to Larry’s question earlier, but I’m looking at the stock down kind of mid- to upper single digits in the aftermarket. I think it’s on this guidance commentary. And again, the high end of the range gets you to that 25%. Was it a street modeling issue at 25% versus where it should have been 23%, 24%. I’m just making sure there’s nothing competitively or pharmacy related that we should really be worried about? And then the real question is, Jim, when you guys came out with O 5, I think you went from 80/20 MDI to competitive conversions all the way to 60-40, and then it went to 70-30, now we’re back to 80-20. Is it getting tougher and tougher to take those competitive conversions? And with G7, do you think that will start to get a little bit better, a little bit easier throughout the course of this year?

Jim Hollingshead: Why don’t — we’ll have Lauren start on the guide and then I’ll pick up on the competition. Go ahead, Lauren.

Lauren Budden: Sure. So for 2024, even with the significant volume benefit that we realized in ’23, we’re guarding to very strong revenue growth. We expect to achieve almost $2 billion in revenue and our guide represents $300 million of revenue growth in terms of dollars. So your question in terms of what changed from the call we provided, it was really just that revenue shift of 20 million to 25 million of orders that were — would have been Q1 but were placed in advance of our ERP implementation. So the estimated impact of that is 3 points on the total company and 4 points on U.S. Omnipod. So overall, our guide is strong. And as we’ve mentioned, we have many catalysts for growth in ’24 that’s going to help accelerate it and particularly in the back half with those new customer starts and provide strong revenue growth for the year and into 2025 and beyond.

Deborah Gordon: I’m sorry, Jim. I was just going to say that, you nailed it. I thought I heard you say that U.S. The Street is modeling now 25% on a normalized basis. So if I got that right that you said that the U.S., that’s exactly right for the year on a normalized basis. And Lauren nailed it when she said the 4-point impact. So when Lauren provided some color on the Q3 call that we would be in mid-20s to referring to 24 to 26 around there. And at the midpoint, we’re spot on what we were expecting for U.S. And that’s about — if you do the math, about 21% on a normalized basis for total Omnipod and it gets you to the total company growth of 20%. So it’s spot on from the color that Lauren gave in November. We just didn’t expect that shift, which is the $20 million to $30 million shift that happens, ends up or $20 million to $25 million ends up being double, right, to the 40 to 50 because it’s comes out of one year and goes into the other.

So that’s where actually she was trying to normal set. So hopefully, that answers your question on that piece. Sorry, Jim

Jim Hollingshead: And we can always clarify this offline, right? So — but it’s a decrease in the denominator, increase in the numerator for ’24, you get the normalized number, right? So it’s a double whammy in that $20 million to $25 million. So the underlying guide remains the same, respectively. On the competition, yes, we continue to have really good new customer starts. And historically, we always had 80/20 of MDI and competitive switching. After the launch of Omnipod 5, we obviously caught a lot of competitive switchers, and we’ve done really, really well. We continue to have. So if you think about pre-Omnipod-5 and that 20% of competitive switches and with Omnipod 5 and 20% of competitive switchers, it’s a larger number than it was, right?

So because new customer starts are up overall, so we continue to do very, very well. And the underlying dynamic there is we also retain the vast majority of customers that we get from competitors. Retention is very, very strong. And we said that, we do think — we had the benefit now of hearing our two competitors’ calls, and we have the benefit of seeing what’s happening out in the market. We don’t see — there’s little things around the edges, I would say. We don’t see any fundamental underlying shift in the competitive dynamic. Omnipod 5 continues to be the preferred product. But I would say that one of our competitors has done a better job of staunching the bleeding in their installed base. And so you can see a little bit of that dynamic going on in the market.

But we’re still clearly the preferred offer — clearly winning with MDI and just winning with new customer starts overall very, very clearly in the market.

Operator: Your next question comes from Mike Kratky with Leerink Partners.

Mike Kratky: So you’ve capitalized on having a competitive advantage in type 2 with broad pharmacy access. How are you planning on defending that position in the market as we start to see additional pumps expand into the pharmacy channel on both a near-term basis and then looking ahead to 2025?

Jim Hollingshead: Great question. Thank you. Pharmacy is — our offer — the Omnipod platform offer is much better suited to the pharmacy channel than tubed pumps are, much, much better suited. 2 pumps at the end of the day, continue to be durable equipment. And there’s all kinds of things that I can go into the weeds here and talk about this, but I’ll just say it’s not a surprise that we see competitors trying to figure out how to get in the pharmacy channel with a durable tube pump because we’ve been so successful in establishing the pharmacy channel for AID. And as we would expect, competitors are — we’ve established market leadership across basically the whole range of our offer and competitors are going to chase that. It’s — there’s — what we’ve learned is, there’s a very big learning curve in pharmacy.

It’s very, very different from the DME channel, the economics work better for us because there’s — in all cases, the value is actually in the pump, whether it’s a durable pump or it’s the pod. And the fact that the value is created in our consumable, which is the pod gives us an inherent advantage as we — it starts to get a little abstract, but it gives us an inherent advantage as we’re in that channel. Couple that with the fact that we have very, very wide coverage in the pharmacy channel, we have established contracts across the PBMs. And we’ve had very successful growth with all of our PBM partners. We think we have a very defensible position there. People who use insulin go into the pharmacy to get their insulin, whether they’re getting it from retail pharmacy.

So it’s a great place for them to also get their AID-pump therapy and Omnipod continues to be very uniquely positioned and the value prop of Omnipod in the pharmacy channel will continue to be very uniquely positioned as we go forward.

Operator: Your next question will come from the line of Chris Pasquale with Nephron.

Chris Pasquale: Jim, your comments on what you’ve learned so far from the GO LMR were really interesting. It sounds like that’s going pretty well. But I think I heard the guidance really doesn’t assume any benefit from GO in ’24, which makes it sound like a full launch isn’t planned anytime soon. How are you thinking about the timing for a full launch? And what’s really the gating factor there? What boxes do you need to check before you’re ready to expand the commercialization?

Jim Hollingshead: Yes, great question. The way to think about Omnipod GO is that we hear a different language about this. And I’d just be really clear, we’re not in limited market release with GO, we’re in a commercial pilot, right? And so that’s a step before — I think I said this last quarter on our call as well, that’s a step before an LMR. The product itself is ready. It’s out on patients, it’s fully approved. We continue to grow coverage for it. So that’s a step but we’re ahead of schedule and coverage. So the way to think about the Omnipod GO commercial pilot is the gating factor is not timing, it’s learning, right? So what we’re using it for is to establish the right commercial model, both for GO and for the primary care chain.

And one of the reasons we’re so excited about the pilot is that we are learning an awful lot out of that pilot. And so — and where we’re going to land on this thing, whether we commercialize in ’24 with GO or commercialize — get to more of an FMR in ’24 or sometime in ’25, where we’re going to land is we’re going to be in the primary care channel first and second, one way or another, we’re going to have call points in primary care. And the other thing is we will have the broadest offering for people living with type 2 diabetes who need insulin delivery. So we’re already the market leader with DASH in that space very clearly. We know — we have our pivotal trial going to Omnipod 5. As we said before, we know Omnipod 5 is actually being used off label.

In a lot of cases, we’re not promoting Omnipod 5 off-label, but we’ll have — our goal is to have the label for Omnipod 5 in the short order coming out of our pivotal trial, and we continue to have a plan to file with the FDA for that label extension in ’24, and we’ll have Omnipod GO. And that gives you the whole coverage for people using insulin with type 2 all the way from I’m initiating basal insulin 2, I’m using intensive insulin. And so we’ll have that full portfolio of products, and we’ll have a very clear way to commercialize that in both primary care and in the endocrinology channel. So that’s why I’d say I’m very excited about the commercial pilot with Omnipod GO. We are learning the ton and it’s going to make us much better commercially as we get into that and get that full portfolio on market.

Operator: Our next question will come from the line of Steve Lichtman with Oppenheimer.

Steve Lichtman: As you start opening up the opportunity here to the Libre platform outside the U.S. and then in the U.S., can you give us your latest thoughts on the size of that opportunity. There’s been estimates on what that new opportunity set looks like. It would be great to get your latest color on that.

Jim Hollingshead: Yes. We think it’s a really big opportunity. If you look at the sensor market, you’ve got millions of people using Dexcom sensors and millions of people using Abbott’s sensors. So the G6, G7 family products and the Libre 2 and Libre — now emerging Libre 3 family products by creating the integration across that range. So prioritizing G7, prioritizing Libre 2 plus and then 3 that we’re working in parallel. It opens up a really large substantial market for us. The two — we love working with both of our partners. They both have great technology. They’re both really good partners. Development pathway with both of them is really strong. They’re slightly — they have slightly different positions in the main geographies of the U.S. and Europe in terms of their installed base, but both of them have very large installed bases.

And both of them have, as we’ve always said, CGM pays road for us because people get used to having an on-body experience with a sensor and it makes it much easier for them to then jump to an on-body experience with an Omnipod. And so we think it opens up — you can go look at the market share, the estimated market share for our two partners, but we think the Libre integrations open up a large installed base both in Europe and the U.S. of people who will be ready for Omnipod because they’re used to a on-body CGM experience.

Operator: Your next question will come from the line of Marie Thibault with BTIG.

Sam Eiber: Sam on for Marie. Maybe I can follow up on some of the type 2 comments. And just looking at pivotal data coming up at ADA and then filing for label expansion, how much of an uplift could that be once you do get the expanded label there? Just considering 20%, 25% of new patient starts are already coming from type 2?

Jim Hollingshead: Thanks, Sam. If you just look at the size of the end markets there, and I’ll repeat numbers that we shared before. In the U.S., there are about 1.6 million people living with type 1 diabetes. And if that market is about, probably, something less than 40% penetrated with AID therapy. Then in the type 2 market, there are somewhere between 3 million and 4 million people living with type 2 who are on basal-only therapy. And somewhere around 2.5 million people living with type 2 in the U.S. who need intensive insulin therapy, so basal plus bolus. Omnipod 5 is really aimed at that intensive insulin therapy population, about 2.5 million people in the U.S. And therefore, it’s a larger end market than Omnipod 5 plays in now with its current label.

We know that, that market is less than 5% penetrated with AID therapy. And we are already the market leader in that segment of the market because Omnipod DASH has a label there, and we know we’re the clear market leader in the space. So we’re very optimistic. Omnipod 5 is very easy to use. It takes a lot of the burden off of managing your diabetes. That’s why it’s been so successful in the type 1 population. And we’re very optimistic about that value proposition going into the intensive insulin using type 2 population, which is a larger end market than the one we’re playing in today. So we think it is a really important opportunity and a market that, by the way, will continue to grow over time.

Operator: We have time for one more question. Your final question comes from the line of Danielle Antalffy with UBS.

Danielle Antalffy: Just a question on the wholesaler stocking and that whole dynamic because it is something now we have to start thinking about in the model, But and I know it’s unpredictable. But qualitatively, maybe you could talk about how much visibility you have into when that pod that gets stocked goes on to a patient. I guess trying to get a sense of is this something that’s going to happen to this level every single quarter, if they’re going off the shelves very quickly? How long do the stocking sort of fit on the shelf there?

Lauren Budden: No. I mean it doesn’t really stay on the shelf that long. I mean we — it’s a pretty efficient channel. In terms of the visibility into the date on hand though that’s not something that we ever included in our guidance, and that’s something that we can’t control. And so unfortunately, this quarter, we had the double whammy of them taking the inventory level back up after they had taken them down earlier in the year. And then at the same time, we had the ERP pull forward dynamic. So I don’t expect that we’d see something of that magnitude. But again, when we have something like this, what we do is, we call out and we tell you when it happens, we don’t have the ability to guide to it. It’s not something in our control.

Operator: And we do have time for one more question. That question will come from the line of Matt Miksic with Barclays.

Matt Miksic: Great. So maybe a bit of a 2-parter good news and maybe challenging news question, if I could, just at the end, is — you had mentioned that you’re looking for acceleration on the back of [indiscernible] G7 integration. And I mean given the new patient share that you’re catching now, I just would ask maybe what’s — it’s very high growth, and it’s very high share of new patients. What additional patients do you get with G7 that you’re not already capturing and in the advantage that you seem to be having in the clinic? And then the other question is looking out a year, 18 months or so, not certain, of course, but it certainly seems like there’s going to be, at some point, another tubeless pump on the market from one of your competitors or more.

And so maybe just think about your — how do you think about that? And how do you prepare for that? How do you look to continue your leadership in that segment? And how should we — investors think about that if I can grow potentially.

Jim Hollingshead: Thanks, Matt. I’ll do those in reverse order. The first one is on the tubeless form factor. We obviously watch our competitor pipelines as closely as we can. And in terms of what is out there publicly that we can see, we don’t see anything coming in that time frame that’s even close to what we have in market right now with Omnipod 5, just in terms of the whole package, the convenience, the ease of use, the scalability, the wear experience, automated needle insertion, we could go on and on about the feature set that we are very confident in our competitive position. We’re never complacent. We have a lot of respect for our competitors, and we know that what — because Omnipod in general, but Omnipod 5 has been so successful, everybody wants to chase it.

So that just makes sense, and that’s how competition works. But we are very confident in our competitive position, and we don’t see anything coming in anybody’s pipeline that even matches what we have, and we’re going to continue to drive innovation. So we’re going to extend our lead. On the first part of your question, it’s a really good question. Yes. We’re obviously doing very, very well in the market with our existing offer. And as I said in the prepared remarks, it’s really — we really see it as our minimum viable product, and we’ve done so well with it. But on specifically the G6 and G7, what you’re seeing and it’s — you can go look analytically at the underlying script data, what you’re seeing is G7 is really doing well with new customer starts.

So a lot of people going on to G7. And you guys have heard this is probably corny but you’ve heard me use the metaphor before, about fishing. If you think we’re out fishing in the stock pond, the pond has a lot of G6 in it, but it’s got more and more G7 in it all the time. And so we want to be able to go out there and fish in both bonds and proportionally, G7 is a larger and larger part of the market. We want to — now I’m going to mix metaphors. We want that wind at our back of all the patients coming under G7. We know the offer together, Omnipod 5 and G7 is going to be terrific and drive a lot of growth for us just like Omnipod 5 with G6 had.

Operator: This concludes our Q&A section. I would like to turn the conference back to Jim Hollingshead.

Jim Hollingshead: Thank you, everybody, for joining us today. We are really excited to have delivered another outstanding year for Insulet. We’re focused on extending our leading position with our deep expertise and strong emphasis on innovation, operational excellence and further improving the customer experience. We remain committed to driving value for our shareholders through margin expansion and cash flow generation, all while maintaining our emphasis on investing for growth. I also want to once again thank our outstanding Insulet global team for their dedication and their focus on innovation and passion to our customers. Thank you, everybody. And with that, I’ll thank you all and wish you all a great evening. Good night, everybody.

Operator: Ladies and gentlemen, this concludes today’s conference. Thank you for your participation, and have a wonderful day. You may all disconnect.